Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v15-EN | Version v11-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2019-04-04 | 2019-03-08 |
| Drug Identification Number | 02253631 | 02253631 |
| Brand name | TEVETEN PLUS | TEVETEN PLUS |
| Common or Proper name | TEVETEN PLUS | TEVETEN PLUS |
| Company Name | BGP PHARMA ULC | BGP PHARMA ULC |
| Ingredients | HYDROCHLOROTHIAZIDE EPROSARTAN | HYDROCHLOROTHIAZIDE EPROSARTAN |
| Strength(s) | 12.5MG 600MG | 12.5MG 600MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL | ORAL |
| Packaging size | 2 x 14CA | 2 x 14CA |
| ATC code | C09DA | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
| Anticipated start date | 2019-02-11 | 2019-02-11 |
| Actual start date | ||
| Estimated end date | 2019-04-15 | 2019-04-15 |
| Actual end date | 2019-04-03 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |